Stem Cell Therapy Inhibiting Lymphoid Tissue Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Stem cells injected for tissue regeneration often accumulate in the spleen rather than the target organ, reducing their effectiveness in repairing damaged tissues due to their binding to lymphoid tissues, particularly germinal centers, which limits the degree of functional recovery.
Innovation Solution
Administering stem cells in conjunction with therapeutic agents that inhibit their binding to lymphoid tissues, such as radiation, chemotherapeutic agents, or immune suppressants, specifically targeting CD45 and CD26 antigens, to reduce stem cell localization in the spleen and increase their availability for targeted organ repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cells are injected directly into the target organ for tissue regeneration, then the stem cells can potentially repair damaged tissues, but most stem cells accumulate in the spleen and lymphoid tissues instead of the target organ, reducing their effectiveness
Solution Approach 1:
The patent applies preliminary action by administering therapeutic agents (such as radiation, chemotherapeutic agents, or immune suppressants) before stem cell injection to inhibit the formation or activity of germinal centers in lymphoid tissues. This preliminary modification of the lymphoid tissue environment prevents stem cell sequestration, ensuring that subsequently injected stem cells remain in circulation and can reach the target organ for effective tissue regeneration
Solution Approach 2:
The patent uses therapeutic agents as intermediaries to mediate between the stem cells and the lymphoid tissue system. These agents (radiation, chemotherapeutic agents, immune suppressants) act as mediators that temporarily inhibit germinal center activity, thereby preventing the harmful interaction between stem cells and lymphoid tissues while allowing the beneficial stem cell therapy to proceed
2Reliability
If splenectomy is performed to improve stem cell engraftment and functional recovery, then stem cell retention in the target organ improves, but surgical mortality, sepsis, and thrombotic complications increase
Solution Approach 1:
The patent applies the taking out principle by selectively removing or inhibiting the problematic component (germinal centers in lymphoid tissues) rather than removing the entire organ (spleen). By using therapeutic agents to target and inhibit germinal center activity specifically, the patent achieves the benefit of improved stem cell engraftment without the harmful effects of splenectomy, as the rest of the spleen and other vital functions remain intact
Solution Approach 2:
The patent applies local quality by creating a localized modification in specific regions (germinal centers in lymphoid tissues) rather than globally removing the entire spleen. The therapeutic agents act locally on germinal centers to inhibit their ability to sequester stem cells, while leaving the rest of the spleen and its essential functions (immune surveillance, filtration) intact, thus avoiding the systemic complications of splenectomy
Data Source
AI summary
The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20.